Are you over 18 and want to see adult content?
More Annotations
A complete backup of archcitygranite.com
Are you over 18 and want to see adult content?
A complete backup of websitevalue.co.uk
Are you over 18 and want to see adult content?
A complete backup of cashflowdiary.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.protothema.gr/sports/article/980564/i-exomologisi-tou-vlado-giankovits-irthe-enas-anthropos-tou-panioni
Are you over 18 and want to see adult content?
A complete backup of www.washingtonpost.com/national/2-rhode-island-virus-cases-stem-from-same-europe-school-trip/2020/03/02/e09
Are you over 18 and want to see adult content?
A complete backup of www.acunn.com/magazin/paris-moda-haftasinda-boy-gosteren-bella-hadid-katildigi-partide-dilara-findikoglu-ru
Are you over 18 and want to see adult content?
A complete backup of www.hln.be/sport/voetbal/buitenlands-voetbal/premier-league/tottenham-verslikt-zich-op-eigen-veld-en-lijdt-
Are you over 18 and want to see adult content?
Text
one step ahead.
JUNE 2021 - WHEN WILL THE DUPIXENT PATENTS EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN DO THE PATENTS ON KEYTRUDA EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - PERTUZUMAB BIOSIMILAR EQUIVALENTS, BIOLOGIC DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
DRUG PRICES AND TRENDS FOR ESBRIET DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
DRUG PRICES AND TRENDS FOR XARELTO Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type; XARELTO 10MG TABLETS: J&J obo Janssen Pharmaceuticals, Inc. 50458-0580-90: 90: 914.08 IBRANCE MARKET EXCLUSIVITY PERIOD (MEP). WHEN DO THE DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
NOXAFIL LOSS OF EXCLUSIVITY (LOE). WHEN DO THE PATENTS ON Which patents cover Noxafil, and when can generic versions of Noxafil launch? Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. There are seven patents protecting this drug and three Paragraph IV challenges. TRINTELLIX LOSS OF EXCLUSIVITY (LOE). WHEN DO THE Which patents cover Trintellix, and when can generic versions of Trintellix launch? Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge. TEVA DRUG PIPELINE, GLOBAL PATENTSSEE PATENT LAWSUITS FOR TEVA What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch? TEVA has seven hundred and nine approved drugs. There are JUNE 2021 - WHEN WILL THE REPATHA PATENTS EXPIRE, AND WHEN DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN WILL THE DUPIXENT PATENTS EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN DO THE PATENTS ON KEYTRUDA EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - PERTUZUMAB BIOSIMILAR EQUIVALENTS, BIOLOGIC DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
DRUG PRICES AND TRENDS FOR ESBRIET DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
DRUG PRICES AND TRENDS FOR XARELTO Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type; XARELTO 10MG TABLETS: J&J obo Janssen Pharmaceuticals, Inc. 50458-0580-90: 90: 914.08 IBRANCE MARKET EXCLUSIVITY PERIOD (MEP). WHEN DO THE DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
NOXAFIL LOSS OF EXCLUSIVITY (LOE). WHEN DO THE PATENTS ON Which patents cover Noxafil, and when can generic versions of Noxafil launch? Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. There are seven patents protecting this drug and three Paragraph IV challenges. TRINTELLIX LOSS OF EXCLUSIVITY (LOE). WHEN DO THE Which patents cover Trintellix, and when can generic versions of Trintellix launch? Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge. DRUGPATENTWATCH: MAKE BETTER DECISIONS AROUND BRANDED DRUG Business intelligence on pharmaceutical and biologic drugs - life cycle management, brand erosion, generic entry, biosimilars, 505(b)(2), patents, sales, litigation, and more DRUG PRICES AND TRENDS FOR ESBRIET DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN WILL THE DUPIXENT PATENTS EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN WILL THE PATENTS ON EYLEA EXPIRE, AND Case Name Date; Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. 2020-06-19: Regeneron Pharmaceuticals, Inc. v. Genentech, Inc.2011-02-17
JUNE 2021 - PERTUZUMAB BIOSIMILAR EQUIVALENTS, BIOLOGIC DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
REVLIMID MARKET EXCLUSIVITY PERIOD (MEP). WHEN WILL THE When do Revlimid patents expire, and what generic alternatives are available? Revlimid is a drug marketed by Celgene and is included in one NDA. There are fifteen patents protecting this drug and three Paragraph IV challenges. NEXLETOL LOSS OF EXCLUSIVITY (LOE). WHEN WILL THE NEXLETOL Which patents cover Nexletol, and what generic alternatives are available? Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are six patents protecting this drug. This drug has twenty-three patent family members in thirteen countries. The generic ingredient in NEXLETOL is bempedoic acid.Additional details are available on the bempedoic acid profile page. RYTARY MARKET EXCLUSIVITY PERIOD (MEP). WHEN DO THE When do Rytary patents expire, and when can generic versions of Rytary launch? Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. There are nine patents protecting this drug and two ParagraphIV challenges.
DULERA MARKET EXCLUSIVITY PERIOD (MEP). WHEN WILL THE When do Dulera patents expire, and what generic alternatives are available? Dulera is a drug marketed by Merck Sharp Dohme and is included in one NDA. The generic ingredient in DULERA is formoterol fumarate; mometasone furoate.There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the formoterol fumarate CHANTIX MARKET EXCLUSIVITY PERIOD (MEP). WHEN WILL THE When do Chantix patents expire, and what generic alternatives are available? Chantix is a drug marketed by Pf Prism Cv and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge. TEVA DRUG PIPELINE, GLOBAL PATENTSSEE PATENT LAWSUITS FOR TEVA What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch? TEVA has seven hundred and nine approved drugs. There are ABBVIE DRUG PIPELINE, GLOBAL PATENTS What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch? ABBVIE has eighty-nine approved drugs. There are sixty-nine US 38 DRUGS FACING NCE-1 / ABBREVIATED NEW DRUG APPLICATIONWHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BAXDELA ?GENERIC NAME: DELAFLOXACIN MEGLUMINE NCE-1 DATE: JUNE 2021 BAXDELA IS A DRUG MARKETED BY MELINTA . THERE ARE THIRTEEN PATENTS PROTECTING THIS D...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BEVYXXA ?GENERIC NAME: BETRIXABAN NCE-1 DATE: JUNE 2021 BEVYXXA IS A DRUG MARKETED BY PORTOLA PHARMS INC . THERE ARE FIVE PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST NERLYNX ?GENERIC NAME: NERATINIB MALEATE NCE-1 DATE: JULY 2021 NERLYNX IS A DRUG MARKETED BY PUMA BIOTECH . THERE ARE TEN PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST VOSEVI ?GENERIC NAME: SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR NCE-1 DATE: JULY 2021 VOSEVI IS A DRUG MARKETED BY GILEAD SCIENCES INC . THERE ARE SEVENTEE...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST IDHIFA ?GENERIC NAME: ENASIDENIB MESYLATE NCE-1 DATE: AUGUST 2021 IDHIFA IS A DRUG MARKETED BY CELGENE CORP . THERE ARE SIX PATENTS PROTECTING THIS DRU...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST MAVYRET ?GENERIC NAME: GLECAPREVIR; PIBRENTASVIR NCE-1 DATE: AUGUST 2021 MAVYRET IS A DRUG MARKETED BY ABBVIE INC . THERE ARE SEVEN PATENTS PROTECTING T...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BENZNIDAZOLE ?GENERIC NAME: BENZNIDAZOLE NCE-1 DATE: AUGUST 2021 BENZNIDAZOLE IS A DRUG MARKETED BY CHEMO RESEARCH SL . THIS DRUG HAS FOUR HUNDRED AND FORT...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST ALIQOPA ?GENERIC NAME: COPANLISIB DIHYDROCHLORIDE NCE-1 DATE: SEPTEMBER 2021 ALIQOPA IS A DRUG MARKETED BY BAYER HEALTHCARE . THERE ARE FOUR PATENTS PRO...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST SOLOSEC ?GENERIC NAME: SECNIDAZOLE NCE-1 DATE: SEPTEMBER 2021 SOLOSEC IS A DRUG MARKETED BY LUPIN . THERE ARE FOUR PATENTS PROTECTING THIS DRUG. THIS DR... NCE-1 / Abbreviated New Drug Application acceptance dates for drugs with upcoming New Chemical Entity Exclusivity Expiration dates in 2021- 2022
JUNE 2021 - WHEN WILL THE DUPIXENT PATENTS EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN DO THE PATENTS ON ENTYVIO EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN WILL THE REPATHA PATENTS EXPIRE, AND WHEN DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - PERTUZUMAB BIOSIMILAR EQUIVALENTS, BIOLOGIC Supplementary Protection Certificate SPC Country SPC Expiration SPC Description; 140: Estonia Get Started for $10: 2015 00006: Denmark GetStarted for $10
NEXLETOL LOSS OF EXCLUSIVITY (LOE). WHEN WILL THE NEXLETOL Which patents cover Nexletol, and what generic alternatives are available? Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are six patents protecting this drug. This drug has twenty-three patent family members in thirteen countries. The generic ingredient in NEXLETOL is bempedoic acid.Additional details are available on the bempedoic acid profile page. MAY 2021 - GOLIMUMAB BIOSIMILAR ENTRY, DRUG PATENT EXPIRY DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Start Learning Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN WILL THE PATENTS ON BAVENCIO EXPIRE, AND BAVENCIO patent expiration date, news, international patents,biosimilar launch
TEVA DRUG PIPELINE, GLOBAL PATENTSSEE PATENT LAWSUITS FOR TEVA What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch? TEVA has seven hundred and nine approved drugs. There are ABBVIE DRUG PIPELINE, GLOBAL PATENTS What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch? ABBVIE has eighty-nine approved drugs. There are sixty-nine US 38 DRUGS FACING NCE-1 / ABBREVIATED NEW DRUG APPLICATIONWHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BAXDELA ?GENERIC NAME: DELAFLOXACIN MEGLUMINE NCE-1 DATE: JUNE 2021 BAXDELA IS A DRUG MARKETED BY MELINTA . THERE ARE THIRTEEN PATENTS PROTECTING THIS D...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BEVYXXA ?GENERIC NAME: BETRIXABAN NCE-1 DATE: JUNE 2021 BEVYXXA IS A DRUG MARKETED BY PORTOLA PHARMS INC . THERE ARE FIVE PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST NERLYNX ?GENERIC NAME: NERATINIB MALEATE NCE-1 DATE: JULY 2021 NERLYNX IS A DRUG MARKETED BY PUMA BIOTECH . THERE ARE TEN PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST VOSEVI ?GENERIC NAME: SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR NCE-1 DATE: JULY 2021 VOSEVI IS A DRUG MARKETED BY GILEAD SCIENCES INC . THERE ARE SEVENTEE...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST IDHIFA ?GENERIC NAME: ENASIDENIB MESYLATE NCE-1 DATE: AUGUST 2021 IDHIFA IS A DRUG MARKETED BY CELGENE CORP . THERE ARE SIX PATENTS PROTECTING THIS DRU...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST MAVYRET ?GENERIC NAME: GLECAPREVIR; PIBRENTASVIR NCE-1 DATE: AUGUST 2021 MAVYRET IS A DRUG MARKETED BY ABBVIE INC . THERE ARE SEVEN PATENTS PROTECTING T...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BENZNIDAZOLE ?GENERIC NAME: BENZNIDAZOLE NCE-1 DATE: AUGUST 2021 BENZNIDAZOLE IS A DRUG MARKETED BY CHEMO RESEARCH SL . THIS DRUG HAS FOUR HUNDRED AND FORT...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST ALIQOPA ?GENERIC NAME: COPANLISIB DIHYDROCHLORIDE NCE-1 DATE: SEPTEMBER 2021 ALIQOPA IS A DRUG MARKETED BY BAYER HEALTHCARE . THERE ARE FOUR PATENTS PRO...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST SOLOSEC ?GENERIC NAME: SECNIDAZOLE NCE-1 DATE: SEPTEMBER 2021 SOLOSEC IS A DRUG MARKETED BY LUPIN . THERE ARE FOUR PATENTS PROTECTING THIS DRUG. THIS DR... NCE-1 / Abbreviated New Drug Application acceptance dates for drugs with upcoming New Chemical Entity Exclusivity Expiration dates in 2021- 2022
JUNE 2021 - WHEN WILL THE DUPIXENT PATENTS EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN DO THE PATENTS ON ENTYVIO EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN WILL THE REPATHA PATENTS EXPIRE, AND WHEN DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - PERTUZUMAB BIOSIMILAR EQUIVALENTS, BIOLOGIC Supplementary Protection Certificate SPC Country SPC Expiration SPC Description; 140: Estonia Get Started for $10: 2015 00006: Denmark GetStarted for $10
NEXLETOL LOSS OF EXCLUSIVITY (LOE). WHEN WILL THE NEXLETOL Which patents cover Nexletol, and what generic alternatives are available? Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are six patents protecting this drug. This drug has twenty-three patent family members in thirteen countries. The generic ingredient in NEXLETOL is bempedoic acid.Additional details are available on the bempedoic acid profile page. MAY 2021 - GOLIMUMAB BIOSIMILAR ENTRY, DRUG PATENT EXPIRY DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Start Learning Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN WILL THE PATENTS ON BAVENCIO EXPIRE, AND BAVENCIO patent expiration date, news, international patents,biosimilar launch
DRUGPATENTWATCH: MAKE BETTER DECISIONS AROUND BRANDED DRUG DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
38 DRUGS FACING NCE-1 / ABBREVIATED NEW DRUG APPLICATION NCE-1 / Abbreviated New Drug Application acceptance dates for drugs with upcoming New Chemical Entity Exclusivity Expiration dates in 2021- 2022
JUNE 2021 - BELIMUMAB BIOSIMILAR ENTRY, DRUG PATENT DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - PERTUZUMAB BIOSIMILAR EQUIVALENTS, BIOLOGIC Supplementary Protection Certificate SPC Country SPC Expiration SPC Description; 140: Estonia Get Started for $10: 2015 00006: Denmark GetStarted for $10
JUNE 2021 - WHEN DO THE PATENTS ON PRALUENT EXPIRE, AND Want insights into the biggest revenue-changing events? Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market. DRUG PATENT 2025 PATENT EXPIRY AND GENERIC DRUG ENTRY See Drug Patent Expirations for 2025 . Generic drug entry, freedom to operate, generic drug entry NOXAFIL LOSS OF EXCLUSIVITY (LOE). WHEN DO THE PATENTS ON Which patents cover Noxafil, and when can generic versions of Noxafil launch? Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. There are seven patents protecting this drug and three Paragraph IV challenges. JUNE 2021 - WHEN WILL THE HUMIRA PATENTS EXPIRE, AND WHEN Supplementary Protection Certificate SPC Country SPC Expiration SPC Description; 13/2017: Austria Get Started for $10: PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945/001-002 IDF DER FASSUNG DER ENTSCHEIDUNG DER KOMMISSION C(2015)4704 (MITTEILUNG) 20150707 MYRBETRIQ LOSS OF EXCLUSIVITY (LOE). WHEN DO THE MYRBETRIQ Which patents cover Myrbetriq, and when can generic versions of Myrbetriq launch? Myrbetriq is a drug marketed by Apgdi and is included in two NDAs. There are seven patents protecting this drug and one Paragraph IV challenge. BRILINTA LOSS OF EXCLUSIVITY (LOE). WHEN DO THE BRILINTA Which patents cover Brilinta, and when can generic versions of Brilinta launch? Brilinta is a drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges. DRUGPATENTWATCH: MAKE BETTER DECISIONS AROUND BRANDED DRUGGET THE DAILY BRIEFINGPHARMACEUTICAL INDUSTRY TRENDSMAKE BETTER DECISIONS WITHDRUGPATENTWATCH
DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
38 DRUGS FACING NCE-1 / ABBREVIATED NEW DRUG APPLICATIONWHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BAXDELA ?GENERIC NAME: DELAFLOXACIN MEGLUMINE NCE-1 DATE: JUNE 2021 BAXDELA IS A DRUG MARKETED BY MELINTA . THERE ARE THIRTEEN PATENTS PROTECTING THIS D...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BEVYXXA ?GENERIC NAME: BETRIXABAN NCE-1 DATE: JUNE 2021 BEVYXXA IS A DRUG MARKETED BY PORTOLA PHARMS INC . THERE ARE FIVE PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST NERLYNX ?GENERIC NAME: NERATINIB MALEATE NCE-1 DATE: JULY 2021 NERLYNX IS A DRUG MARKETED BY PUMA BIOTECH . THERE ARE TEN PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST VOSEVI ?GENERIC NAME: SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR NCE-1 DATE: JULY 2021 VOSEVI IS A DRUG MARKETED BY GILEAD SCIENCES INC . THERE ARE SEVENTEE...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST IDHIFA ?GENERIC NAME: ENASIDENIB MESYLATE NCE-1 DATE: AUGUST 2021 IDHIFA IS A DRUG MARKETED BY CELGENE CORP . THERE ARE SIX PATENTS PROTECTING THIS DRU...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST MAVYRET ?GENERIC NAME: GLECAPREVIR; PIBRENTASVIR NCE-1 DATE: AUGUST 2021 MAVYRET IS A DRUG MARKETED BY ABBVIE INC . THERE ARE SEVEN PATENTS PROTECTING T...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BENZNIDAZOLE ?GENERIC NAME: BENZNIDAZOLE NCE-1 DATE: AUGUST 2021 BENZNIDAZOLE IS A DRUG MARKETED BY CHEMO RESEARCH SL . THIS DRUG HAS FOUR HUNDRED AND FORT...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST ALIQOPA ?GENERIC NAME: COPANLISIB DIHYDROCHLORIDE NCE-1 DATE: SEPTEMBER 2021 ALIQOPA IS A DRUG MARKETED BY BAYER HEALTHCARE . THERE ARE FOUR PATENTS PRO...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST SOLOSEC ?GENERIC NAME: SECNIDAZOLE NCE-1 DATE: SEPTEMBER 2021 SOLOSEC IS A DRUG MARKETED BY LUPIN . THERE ARE FOUR PATENTS PROTECTING THIS DRUG. THIS DR... Generic name: ozenoxacin. NCE-1 Date: December 2021. XEPI is a drug marketed by Ferrer Internacional. There are three patents protecting this drug. This drug has fifty patent family members in twenty-five countries. The generic ingredient in XEPI is ozenoxacin. There is JUNE 2021 - WHEN WILL THE DUPIXENT PATENTS EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - BELIMUMAB BIOSIMILAR ENTRY, DRUG PATENT DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN DO THE PATENTS ON ENTYVIO EXPIRE, AND Country. Patent Number. Estimated Expiration. South Africa. 201308069. Get Started for $10. World Intellectual Property Organization (WIPO) 2016139482. Get Started for $10. WHICH DRUGS CONTAIN CHOLESTEROL? CONNECTING INACTIVE DrugPatentWatch Database Preview. Drugs Containing Excipient (Inactive Ingredient) CHOLESTEROL. Send this page by email Email this page to acolleague
JUNE 2021 - PEMBROLIZUMAB BIOSIMILAR EQUIVALENTS, DRUG DrugPatentWatch Database Preview. Pembrolizumab - Biologic Drug Details. Send this page by email Email this page to a colleague NOXAFIL LOSS OF EXCLUSIVITY (LOE). WHEN DO THE PATENTS ON Which patents cover Noxafil, and when can generic versions of Noxafil launch? Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. There are seven patents protecting this drug and three Paragraph IV challenges. JUNE 2021 - WHEN DO THE PATENTS ON PRALUENT EXPIRE, AND PRALUENT patent expiry, news, international patents, biosimilar launch PRADAXA MARKET EXCLUSIVITY PERIOD (MEP). WHEN DO THE When do Pradaxa patents expire, and when can generic versions of Pradaxa launch? Pradaxa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges. DRUGPATENTWATCH: MAKE BETTER DECISIONS AROUND BRANDED DRUGGET THE DAILY BRIEFINGPHARMACEUTICAL INDUSTRY TRENDSMAKE BETTER DECISIONS WITHDRUGPATENTWATCH
DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
38 DRUGS FACING NCE-1 / ABBREVIATED NEW DRUG APPLICATIONWHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BAXDELA ?GENERIC NAME: DELAFLOXACIN MEGLUMINE NCE-1 DATE: JUNE 2021 BAXDELA IS A DRUG MARKETED BY MELINTA . THERE ARE THIRTEEN PATENTS PROTECTING THIS D...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BEVYXXA ?GENERIC NAME: BETRIXABAN NCE-1 DATE: JUNE 2021 BEVYXXA IS A DRUG MARKETED BY PORTOLA PHARMS INC . THERE ARE FIVE PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST NERLYNX ?GENERIC NAME: NERATINIB MALEATE NCE-1 DATE: JULY 2021 NERLYNX IS A DRUG MARKETED BY PUMA BIOTECH . THERE ARE TEN PATENTS PROTECTING THIS DRUG....WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST VOSEVI ?GENERIC NAME: SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR NCE-1 DATE: JULY 2021 VOSEVI IS A DRUG MARKETED BY GILEAD SCIENCES INC . THERE ARE SEVENTEE...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST IDHIFA ?GENERIC NAME: ENASIDENIB MESYLATE NCE-1 DATE: AUGUST 2021 IDHIFA IS A DRUG MARKETED BY CELGENE CORP . THERE ARE SIX PATENTS PROTECTING THIS DRU...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST MAVYRET ?GENERIC NAME: GLECAPREVIR; PIBRENTASVIR NCE-1 DATE: AUGUST 2021 MAVYRET IS A DRUG MARKETED BY ABBVIE INC . THERE ARE SEVEN PATENTS PROTECTING T...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST BENZNIDAZOLE ?GENERIC NAME: BENZNIDAZOLE NCE-1 DATE: AUGUST 2021 BENZNIDAZOLE IS A DRUG MARKETED BY CHEMO RESEARCH SL . THIS DRUG HAS FOUR HUNDRED AND FORT...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST ALIQOPA ?GENERIC NAME: COPANLISIB DIHYDROCHLORIDE NCE-1 DATE: SEPTEMBER 2021 ALIQOPA IS A DRUG MARKETED BY BAYER HEALTHCARE . THERE ARE FOUR PATENTS PRO...WHEN CAN DRUG PATENT CHALLENGES BE FILED AGAINST SOLOSEC ?GENERIC NAME: SECNIDAZOLE NCE-1 DATE: SEPTEMBER 2021 SOLOSEC IS A DRUG MARKETED BY LUPIN . THERE ARE FOUR PATENTS PROTECTING THIS DRUG. THIS DR... Generic name: ozenoxacin. NCE-1 Date: December 2021. XEPI is a drug marketed by Ferrer Internacional. There are three patents protecting this drug. This drug has fifty patent family members in twenty-five countries. The generic ingredient in XEPI is ozenoxacin. There is JUNE 2021 - WHEN WILL THE DUPIXENT PATENTS EXPIRE, AND DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - BELIMUMAB BIOSIMILAR ENTRY, DRUG PATENT DrugPatentWatch Video Training Decision-making for generic drug entry and branded drug lifecycle management Get Your Certificate Today. By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stayone step ahead.
JUNE 2021 - WHEN DO THE PATENTS ON ENTYVIO EXPIRE, AND Country. Patent Number. Estimated Expiration. South Africa. 201308069. Get Started for $10. World Intellectual Property Organization (WIPO) 2016139482. Get Started for $10. WHICH DRUGS CONTAIN CHOLESTEROL? CONNECTING INACTIVE DrugPatentWatch Database Preview. Drugs Containing Excipient (Inactive Ingredient) CHOLESTEROL. Send this page by email Email this page to acolleague
JUNE 2021 - PEMBROLIZUMAB BIOSIMILAR EQUIVALENTS, DRUG DrugPatentWatch Database Preview. Pembrolizumab - Biologic Drug Details. Send this page by email Email this page to a colleague NOXAFIL LOSS OF EXCLUSIVITY (LOE). WHEN DO THE PATENTS ON Which patents cover Noxafil, and when can generic versions of Noxafil launch? Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. There are seven patents protecting this drug and three Paragraph IV challenges. JUNE 2021 - WHEN DO THE PATENTS ON PRALUENT EXPIRE, AND PRALUENT patent expiry, news, international patents, biosimilar launch PRADAXA MARKET EXCLUSIVITY PERIOD (MEP). WHEN DO THE When do Pradaxa patents expire, and when can generic versions of Pradaxa launch? Pradaxa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges. DRUGS COMING OFF PATENT: INTERNATIONAL PATENTS, GENERICS DrugPatentWatch ® Estimated Upcoming Generic Entry Dates Anticipated Loss-of-Exclusivity (LOE) dates for branded drugs. Unapproved (DESI) Drugs. Upcoming 180-Day Patent Challenge Exclusivity Expirations 45 DRUGS FACING PATENT EXPIRATIONS AND GENERIC ENTRY IN DrugPatentWatch ® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2022. Generic Entry Controlled by: Patent 6,821,987. FOTIVDA is a drug marketed by Aveo Pharms. There are two patents protecting this drug. The generic ingredient in FOTIVDA is tivozanibhydrochloride.
ABBVIE DRUG PIPELINE, GLOBAL PATENTS PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516. 2673237. 1990016-6. Sweden. Get Started for $10. PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REG. NO/DATE: EU/1/17/1173 20180326. >Patent Number. >Supplementary Protection Certificate. JUNE 2021 - WHEN DO THE PATENTS ON PRALUENT EXPIRE, AND PRALUENT patent expiry, news, international patents, biosimilar launch ADUCANUMAB PATENTS AND CLINICAL TRIALS: DRUG PIPELINE Aducanumab is an investigational drug. There have been 8 clinical trials for Aducanumab. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1 st 2015. The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and Cognitive Dysfunction. XIFAXAN LOSS OF EXCLUSIVITY (LOE). WHEN WILL THE PATENTS Which patents cover Xifaxan, and what generic alternatives are available? Xifaxan is a drug marketed by Salix Pharms and is included in two NDAs. There are twenty-seven patents protecting this drug and two Paragraph IV challenges. ABRAXANE LOSS OF EXCLUSIVITY (LOE). WHEN WILL THE PATENTS Which patents cover Abraxane, and what generic alternatives are available? Abraxane is a drug marketed by Abraxis Bioscience and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge. DULERA MARKET EXCLUSIVITY PERIOD (MEP). WHEN WILL THE When do Dulera patents expire, and what generic alternatives are available? Dulera is a drug marketed by Merck Sharp Dohme and is included in one NDA. The generic ingredient in DULERA is formoterol fumarate; mometasone furoate.There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the formoterol fumarate BRIDION MARKET EXCLUSIVITY PERIOD (MEP). WHEN DO THE When do Bridion patents expire, and when can generic versions of Bridion launch? Bridion is a drug marketed by Organon Sub Merck and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge. ZYTIGA LOSS OF EXCLUSIVITY (LOE). WHEN WILL THE ZYTIGA Which patents cover Zytiga, and what generic alternatives are available? Zytiga is a drug marketed by Janssen Biotech and is included in one NDA. The generic ingredient in ZYTIGA is abiraterone acetate.There are twenty-five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.DrugPatentWatch
__ Log In Blog
Newsletter
Contact Start TrialPricing
Serving leading biopharmaceutical companies globally: MAKE BETTER DECISIONS … AROUND BRANDED DRUG LIFECYCLE MANAGEMENT AND GENERIC ENTRY WITH ACCURATE, OBJECTIVE, AND TIMELY INTELLIGENCE__ START TRIAL
See Plans and Pricing DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more … SOLUTIONS DESIGNED FOR ALL YOUR NEEDS Reliable primary data + expert analysis. We provide answers for yourburning questions
See Plans and Pricing → GENERIC FIRST ENTRANTS How do we identify generic entrants before they get FDA approval?Read Article
LAW FIRM BUSINESS DEVELOPMENT Identify clients for patent litigation support.Read Article
DAY 181 GENERIC DRUG LAUNCH A Fast and Cheap Way to Find Generic Entry OpportunitiesRead Article
FIND AND EVALUATE BUSINESS OPPORTUNITIES * Assess levels of generic competition * Use drug price ranges to evaluate price elasticity * Determine optimal prices before launch__ START TRIAL
See Plans and PricingGLOBAL DRUG PATENTS
* Drug Patents in 134 Countries * Evaluate branded and generic market opportunities globally__ START TRIAL
See Plans and Pricing REFINE YOUR MARKET-ENTRY STRATEGY * Assess market potential through historic sales figures * Evaluate buyer power with data on reimbursement segmentation * Align distribution methods with information on where and how drugsare purchased
__ START TRIAL
See Plans and Pricing MONITOR 505(B)(2) AND BIOSIMILAR ACTIVITY * Anticipate 505(b)(2) and biosimilar approvals * Track OTC-switches, new formulations, biosimilars, and other drugimprovements
* Strengthen new formulation patents by studying prior claims andlitigation
__ START TRIAL
See Plans and Pricing GET CONFIDENTIAL ROYALTY AND SETTLEMENT TERMS * Study failed patent challenges to develop a better strategy * Collect competitive intelligence by examining contractual disputes * Track litigation to anticipate early generic entry__ START TRIAL
See Plans and Pricing FIND GENERIC DRUG ENTRY OPPORTUNITIES * Inform portfolio management decisions * Sector landscaping and due diligence * Track drugs in development and explore new indications forexisting drugs
__ START TRIAL
See Plans and Pricing Serving leading biopharmaceutical companies globally:×
ALERTS AVAILABLE WITH SUBSCRIPTION Alerts are available for users with active subscriptions. Visit the Subscription Options page for details onplans and pricing.
__ Copyright 2002-2020 thinkBiotech LLCISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives LOE / Major Patent Expirations 2020 - 2021 NCE-1 Patent Challenge Dates 2020 - 2021Preferred Citation:
Friedman, Yali. "DrugPatentWatch" _DrugPatentWatch_, thinkBiotech, 2020, www.DrugPatentWatch.com ._ LINKS
* About
* Blog
* Bulk Data for Financial Modeling* Contact
* Database Preview
* Pricing
_ FOLLOW DRUGPATENTWATCH: By using our website you are consenting to our use of cookies in accordance with our privacy policy . I agree×
ACCESS THE COMPLETE DATABASE MAKE BETTER DECISIONS * Analyze global market entry opportunities * Identify first generic entrants * Uncover prior art in expired and abandoned patents➤ START TRIAL
or, see Plans & PricingSomeone from Nacka
Just purchased a subscription » see Plans and Pricing Verified by Evidence3
hours ago
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0